News
1don MSN
Dr. Reddy’s Laboratories (RDY) and Alvotech Enter Into a Collaboration and License Agreement
Dr. Reddy’s Laboratories Limited (NYSE:RDY) is one of the Best Indian Stocks to Buy for Next 5 Years. Dr. Reddy’s ...
7d
Zacks Investment Research on MSNDown 6.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Alvotech (ALVO)
Alvotech (ALVO) has been on a downward spiral lately with significant selling pressure. After declining 6.6% over the past ...
Alvotech (NASDAQ:ALVO) is one of the best oversold NASDAQ stocks to buy now. On July 9, Alvotech (NASDAQ:ALVO) announced that ...
Alvotech stock has dropped despite strong fundamentals and rapid sales growth. Read about ALVO's projected revenue, debt ...
Alvotech acquires Swiss packaging firm Ivers-Lee to boost biosimilar production capacity ahead of three 2025 launches.
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...
— Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global ...
1don MSN
Dr Reddy's Labs Q1 Results: Net profit rises just 1.4% YoY to ₹1,409 crore; revenue surges 11%
Dr Reddy's Laboratories reported a 1.4% increase in consolidated net profit to ₹1,409 crore for Q1FY26, compared to ₹1,392 ...
Alvotech partnered with Kashiv BioSciences for the development of the proposed Xolair® biosimilar, which is referred to as AVT23 by Alvotech and as ADL-018 by Kashiv Biosciences. Use of trademarks ...
Alvotech and Fuji Pharma, a Japanese pharmaceutical company, have decided to expand their exclusive commercialization partnership to include a new undisclosed biosimilar candidate.
REYKJAVIK, Iceland--(BUSINESS WIRE)--Alvotech Holdings S.A. (“Alvotech”), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for ...
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the acquisition of Xbrane ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results